Open label-Locally Advance/metastatic HR +/HER2 negative Breast cancer
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)
ClinicalTrials.gov ID NCT05840211
Protocol number GS-US-598-6168
Sponsor Gilead Sciences
Open label- Early Breast Cancer ER+/Her2 – Intermediate/high recurrence risk
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)
ClinicalTrials.gov ID NCT05774951
Protocol number D8531C00002
Sponsor AstraZeneca
Observational- T-DXd (enhertu) 1st or 2nd line for HER2+, and HER2-low unresectable/metastatic breast cancer
An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer (DB RESPOND)
ClinicalTrials.gov IDNCT05592483
Protocol number D9673R00025
Sponsor AstraZeneca
Observational Solid tumor multi-cohort study
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE)
ClinicalTrials.gov ID NCT05059444
Protocol number 02-MX-003
Sponsor Guardant Health, Inc.
Stage I to II Non-small cell lung cancer
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (PACIFIC-4)
ClinicalTrials.gov ID NCT03833154
Protocol number D9103C00001
Sponsor AstraZeneca
Locally Advanced (Stage III),Un-resectable non-small cell lung cancer
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)
ClinicalTrials.gov ID NCT05211895
Protocol number D9075C00001
Sponsor AstraZeneca
Previously untreated – First line Locally Advanced/metastatic non-small cell lung cancer
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
ClinicalTrials.gov ID NCT05555732
Protocol number DS1062-A-U303
Sponsor Daiichi Sankyo
Open label Stage IIIB, IIIC, IV First line non-small cell lung cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)
Open label advanced or metastatic 2nd or 3rd line non-small cell lung cancer
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)
ClinicalTrials.gov ID NCT05450692
Protocol number D533BC00001
Sponsor AstraZeneca
Newly diagnosed untreated LS-small cell lung cancer
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Open label relapsed small cell lung cancer
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
ClinicalTrials.gov ID NCT05153239
Protocol number PM1183-C-008-21
Sponsor PharmaMar
Relapsed refractory diffused large B cell lymphoma
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
ClinicalTrials.gov ID NCT04442022
Protocol number XPORT-DLBCL-030
Sponsor Karyopharm Therapeutics Inc
Metastatic castrate resistant prostate cancer
Head and Neck Squamous Cell Carcinoma
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma (ELEVATE HNSCC)
ClinicalTrials.gov ID NCT04854499
Protocol number GS-US-548-5916
Sponsor Gilead Sciences
Relapsed or refractory Myelofibrosis
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
ClinicalTrials.gov ID NCT04468984
Protocol number M20-178
Sponsor AbbVie